| ［1］ |
Reynolds NJ, Al⁃Daraji WI. Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology［J］. Clin Exp Dermatol, 2002, 27（7）: 555⁃561.
|
| ［2］ |
Garrido Colmenero C, Blasco Morente G, Tercedor Sánchez J. Oral cyclosporine weekend therapy: a new maintenance therapeutic option in patients with severe atopic dermatitis［J］. Pediatr Dermatol, 2015, 32（4）: 551⁃552. DOI: 10.1111/pde.12592.
|
| ［3］ |
Khattri S, Shemer A, Rozenblit M, et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology［J］. J Allergy Clin Immun, 2014, 133（6）: 1626⁃1634. DOI: 10.1016/j.jaci.2014.03.003.
|
| ［4］ |
Flohr C, Irvine AD. Systemic therapies for severe atopic dermatitis in children and adults［J］. J Allergy Clin Immun, 2013, 132（3）: 774⁃774. DOI: 10.1016/j.jaci.2013.03.016.
|
| ［5］ |
Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis［J］. J Am Acad Dermatol, 2014, 71（2）:327⁃349. DOI: 10.1016/j.jaad.2014.03.030.
|
| ［6］ |
Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema ⁃ a systematic review and meta⁃analysis［J］. J Eur Acad Dermatol Venereol, 2007, 21（5）: 606⁃619.
|
| ［7］ |
Harper JI, Ahmed I, Barclay G, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy［J］. Br J Dermatol, 2000, 142（1）: 52⁃58.
|
| ［8］ |
Plötz SG, Wiesender M, Todorova A, et al. What is new in atopic dermatitis/eczema?［J］. Expert Opin Emerg Dr, 2014, 19（4）: 441⁃458. DOI: 10.1517/14728214.2014.953927.
|
| ［9］ |
Rudloff I, Bachmann M, Pfeilschifter J, et al. Mechanisms of Rapid Induction of Interleukin⁃22 in Activated T Cells and Its Modulation by Cyclosporin A［J］. J Biol Chem, 2012, 287（7）: 4531⁃4543. DOI: 10.1074/jbc.M111.286492.
|
| ［10］ |
Keaney T C, Bhutani T, Sivanesan P, et al. Open⁃label, pilot study examining sequential therapy with oral tacrolimus and topical tacrolimus for severe atopic dermatitis［J］. J Am Acad Dermatol, 2012, 67（4）: 636⁃641. DOI: 10.1016/j.jaad.2011.10.033.
|
| ［11］ |
Wolff K, Fleming C, Hanifin J, et al. Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial［J］. Br J Dermatol, 2005, 152（6）: 1296⁃1303.
|
| ［12］ |
Tiede I, Fritz G, Strand S, et al. CD28⁃dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes［J］. J Clin Invest, 2003, 111（8）: 1133⁃1145.
|
| ［13］ |
Hon KL, Ching GK, Leung TF, et al. Efficacy and tolerability at 3 and 6 months following use of azathioprine for recalcitrant atopic dermatitis in children and young adults［J］. J Dermatolog Treat, 2009, 20（3）: 141⁃145. DOI: 10.1080/09546630802512646.
|
| ［14］ |
Caufield M, Tom WL. Oral azathioprine for recalcitrant pediatric atopic dermatitis: Clinical response and thiopurine monitoring［J］. J Am Acad Dermatol, 2013, 68（1）: 29⁃35. DOI: 10.1016/j.jaad.2012.07.001.
|
| ［15］ |
Murphy LA, Atherton D. A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression［J］. Br J Dermatol, 2002, 147（2）: 308⁃315.
|
| ［16］ |
Firooz A, Ghandi N, Hallaji Z, et al. Role of thiopurine methyl⁃transferase activity in the safety and efficacy of azathioprine in the treatment of pemphigus vulgaris［J］. Arch Dermatol, 2008, 144（9）: 1143⁃1147. DOI: 10.1001/archderm.144.9.1143.
|
| ［17］ |
McAleer MA, Flohr C, Irvine AD. Management of difficult and severe eczema in childhood［J］. BMJ, 2012, 345（jul23 2）: e4770.DOI: 10.1136/bmj.e4770.
|
| ［18］ |
Weatherhead SC, Wahie S, Reynolds NJ, et al. An open⁃label, dose⁃ranging study of methotrexate for moderate-to⁃severe adult atopic eczema［J］. Br J Dermatol, 2007, 156（2）: 346⁃351.
|
| ［19］ |
Sigmundsdottir H, Johnston A, Gudjonsson JE, et al. Methotrexate markedly reduces the of vascular E⁃selectin, cutaneous lymphocyte⁃associated antigen and the numbers of mononuclear leucocytes in psoriatic skin［J］. Exp Dermatol, 2004, 13（7）: 426⁃434.
|
| ［20］ |
Deo M, Yung A, Hill S, et al. Methotrexate for treatment of atopic dermatitis in children and adolescents［J］. Int J Dermatol, 2014, 53（8）: 1037⁃1041. DOI: 10.1111/ijd.12314.
|
| ［21］ |
Werfel T, Schwerk N, Hansen G. The diagnosis and graded therapy of atopic dermatitis［J］. Dtsch Arztebl Int, 2014, 21, 111（29⁃30）: 509⁃520. DOI: 10.3238/arztebl.2014.0509.
|
| ［22］ |
El⁃Khalawany MA, Hassan H, Shaaban D, et al. Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt［J］. Eur J Pediatr, 2013, 172（3）: 351⁃356. DOI: 10.1007/s00431⁃012⁃1893⁃3.
|
| ［23］ |
Heller M, Shin HT, Orlow SJ, et al. Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients［J］. Br J Dermatol, 2007, 157（1）: 127⁃132.
|
| ［24］ |
Haeck IM, Knol MJ, Ten Berge O, et al. Enteric⁃coated myco⁃phenolate sodium versus cyclosporin A as long⁃term treatment in adult patients with severe atopic dermatitis:a randomized controlled trial［J］. J Am Acad Dermatol, 2011, 64（6）: 1074⁃1084. DOI: 10.1016/j.jaad.2010.04.027.
|
| ［25］ |
Sánchez FA, Calvo N, Moreno MA, et al. Better mycophenolic acid 12⁃hour trough level after enteric⁃coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil［J］. Transpl P, 2007, 39（7）: 2194⁃2196.
|
